Renal effects of the inhibitor of thromboxane A2-synthetase OKY-046

Summary Acute renal failure (ARF) was associated with increased urinary thromboxane (TXA₂) excretion and lessened excretion of sodium (U_NaV) and fractional excretion of sodium (FE_Na%). The inhibitor of thromboxane A₂-synthetase OKY-046 enhanced sodium excretion and fractional excretion of sodium in normal and saline loaded animals whereas it partially prevented the reduction in sodium excretion and creatinine clearance and significantly increased fractional excretion of sodium in glycerol treated rats suggesting a partial protection against the development of acute renal failure.Acknowledgment. This work was supported by the Public Benefit Foundation Alexander S. Onassis (G-73). We thank ONO Pharmaceutical Co. Ltd, Kissei Pharmaceutical Co. Ltd, Osaka, Japan, and Dr A Hornych for their generous donations of OKY-046 and anti6keto-PGF_1a antibodies respectively.